{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:01:50Z","timestamp":1773792110215,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T00:00:00Z","timestamp":1416787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007217","name":"VA Health Services Research and Development Service","doi-asserted-by":"crossref","award":["IIR 12-059-2"],"award-info":[{"award-number":["IIR 12-059-2"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH"},{"name":"NIA","award":["K01 AG037593"],"award-info":[{"award-number":["K01 AG037593"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>New drugs therapies have revolutionized the treatment of hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) infection. The objectives of this study were to evaluate uptake and utilization of boceprevir and telaprevir in the Department of Veterans Affairs (<jats:styled-content style=\"fixed-case\">VA<\/jats:styled-content>). We evaluated whether therapies conformed to response\u2010guided protocols, whether they replaced standard interferon plus ribavirin treatment, and whether <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201028B was used to guide treatment. We performed an administrative data\u2010based analysis of all patients receiving pharmacologic treatment for <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">VA<\/jats:styled-content> from October 2009 to July 2013. There were 12\u00a0737 new <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> prescriptions in <jats:styled-content style=\"fixed-case\">VA<\/jats:styled-content> during this time, with 5564 boceprevir or telaprevir prescriptions (44%) and 7173 prescriptions (56%) written for standard interferon plus ribavirin treatment. Prescriptions for the new treatments heavily favoured boceprevir <jats:italic>vs<\/jats:italic> telaprevir (83% <jats:italic>vs<\/jats:italic> 17%). Sixty\u2010two percent (62%) of boceprevir\u2010treated patients completed their minimum\u2010specified protocol, while 69.2% of telaprevir\u2010treated patients completed their minimum\u2010specified protocol. From October 2010 to July 2012, 4090 patients had an <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201028B test; less than 16% of these tests guided subsequent <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> prescriptions. Uptake of boceprevir and telaprevir was rapid; the number of patients initiating treatment approximately doubled in the period after their introduction. While new prescriptions favor boceprevir or telaprevir over standard interferon plus ribavirin therapy, there appears to still be a strong role of interferon plus ribavirin in treating <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> patients. This work can inform our understanding of how other new effective <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> therapies will be used, their diffusion, and the timing of their diffusion in actual clinical practice.<\/jats:p>","DOI":"10.1111\/jvh.12344","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T06:01:43Z","timestamp":1416808903000},"page":"489-495","source":"Crossref","is-referenced-by-count":7,"title":["Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans"],"prefix":"10.1111","volume":"22","author":[{"given":"R.","family":"Gidwani","sequence":"first","affiliation":[{"name":"VA Health Economics Resource Center Menlo Park CA USA"},{"name":"VA Center for Innovation to Implementation Menlo Park CA USA"},{"name":"Department of Medicine Stanford University Stanford CA USA"},{"name":"Center for Health Policy\/Center for Primary Care and Outcomes Research Stanford University Stanford CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. G.","family":"Barnett","sequence":"additional","affiliation":[{"name":"VA Health Economics Resource Center Menlo Park CA USA"},{"name":"Department of Health Research and Policy Stanford University Stanford CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. D.","family":"Goldhaber\u2010Fiebert","sequence":"additional","affiliation":[{"name":"Department of Medicine Stanford University Stanford CA USA"},{"name":"Center for Health Policy\/Center for Primary Care and Outcomes Research Stanford University Stanford CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Asch","sequence":"additional","affiliation":[{"name":"VA Center for Innovation to Implementation Menlo Park CA USA"},{"name":"Department of Medicine Stanford University Stanford CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lo","sequence":"additional","affiliation":[{"name":"VA Health Economics Resource Center Menlo Park CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. K.","family":"Dally","sequence":"additional","affiliation":[{"name":"VA Health Economics Resource Center Menlo Park CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. K.","family":"Owens","sequence":"additional","affiliation":[{"name":"VA Center for Innovation to Implementation Menlo Park CA USA"},{"name":"Department of Medicine Stanford University Stanford CA USA"},{"name":"Center for Health Policy\/Center for Primary Care and Outcomes Research Stanford University Stanford CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908193410802"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.06.051"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.013"},{"key":"e_1_2_8_14_1","unstructured":"Merck & Co. FDA Antiviral Drugs Advisory Committee Meeting.Boceprevir Capsules (NDA 202\u2013258). Briefing Document.Silver Spring MD:U.S. Food and Drug Administration; 29 March2011. Available at:www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM252343.pdf(accessed 3 November 2011)."},{"key":"e_1_2_8_15_1","unstructured":"Vertex Pharmaceuticals.Telaprevir 375\u2010mg Film\u2010Coated Tablet for the Treatment of Genotype 1 Chronic Hepatitis C. Antiviral Drugs Advisory Committee. Briefing Document (NDA 201\u2010917).Silver Spring MD:U.S. Food and Drug Administration; 28 April2011. Available at:www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM252562.pdf(3 November 2011)."},{"key":"e_1_2_8_16_1","unstructured":"Department of Veterans Affairs Veterans Health Administration Public Health Strategic Health Care Group. State of Care for Veterans with Chronic Hepatitis C. November2010. Available at :http:\/\/www.hepatitis.va.gov\/provider\/policy\/HCV-state-of-care-2010.asp(accessed 14 October 2014)."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.48"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.03.006"},{"issue":"8","key":"e_1_2_8_19_1","first-page":"1371","article-title":"Comparison of boceprevir to telaprevir regimens for hepatitis C virus infection in a nationwide study of 4455 patients","volume":"12","author":"Ioannaou GN","year":"2013","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12344","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:10:34Z","timestamp":1695539434000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,24]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/jvh.12344"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12344","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,24]]}}}